Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 9—September 2022

Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic Studies

Michael Loesche1, Elizabeth W. Karlson1, Opeyemi Talabi, Guohai Zhou, Natalie Boutin, Rachel Atchley, Gideon Loevinsohn, Jun Bai Park Chang, Mohammad A. Hasdianda, Adetoun Okenla, Elizabeth Sampson, Haley Schram, Karen Magsipoc, Kirsten Goodman, Lauren Donahue, Maureen MacGowan, Lewis A. Novack, Petr Jarolim, Lindsey R. Baden2, and Eric J. Nilles2Comments to Author 
Author affiliations: Brigham and Womens Hospital, Boston, Massachusetts, USA (M. Loesche, E.W. Karlson, O. Talabi, G. Zhou, N. Boutin, R. Atchley, G. Loevinsohn, J.B.P. Chang, M.A. Hasdianda, A. Okenla, E. Sampson, H. Schram, K. Magsipoc, K. Goodman, L. Donahue, M. MacGowan, L.A. Novak, P. Jarolim, L.R. Baden, E.J. Nilles); Massachusetts General Hospital, Boston (M. Loesche, G. Loevinsohn); Harvard Medical School, Boston (E.W. Karlson, G. Zhou, M.A. Hasdianda, P. Jarolim, L.R. Baden, E.J. Nilles); Harvard Humanitarian Initiative, Cambridge, Massachusetts, USA (E.J. Nilles)

Main Article


SARS-CoV-2 nucleocapsid total immunoglobulin seroreversion by GAMM and half-life methods, by months from infection, among healthcare workers in Boston, Massachusetts, USA, 2020*

Months GAMM, % (95% CI) Half-life, % (95% CI)
4 0 (0–4.9) 0.6 (0.6–0.6)
6 2.7 (3.0–9.5) 1.2 (1.0–1.3)
8 5.5 (1.5–13.4) 2.1 (1.8–2.6)
10 9.6 (3.9–18.8) 3.8 (2.9- 4.8)
12 11 (4.9–20.5) 6.2 (4.7–8.3)
14 12.3 (5.8–22.1) 9.8 (7.2–13.3)
16 13.7 (6.8–23.8) 14.8 (10.6–20.1)
18 15.1 (7.8–25.4) 21.1 (15.0–28.7)
24 NC 48.9 (36.1–62.1)

*The GAMM method estimates are restricted to observational data and therefore not calculated more than 18 months postinfection. Half-life method represents constant log linear antibody contraction with an estimated peak total nucleocapsid antibody level that had a cutoff index of 37 and a half-life of 128 days. GAMM, generalized additive mixed model; NC, not calculated.

Main Article

1These first authors contributed equally to this article.

2These senior authors contributed equally to this article.

Page created: June 09, 2022
Page updated: August 19, 2022
Page reviewed: August 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.